CatalystFDA/Bio

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

Pivotal Phase 3 plans for verekitug target two indications, signaling major clinical advancement.

What changed

Pivotal Phase 3 plans for verekitug target two indications, signaling major clinical advancement.

Why it matters

Pivotal Phase 3 plans for verekitug target two indications, signaling major clinical advancement. — impact context not separately stored; see What changed.

Sources

eodhd